How are we changing clinical trials?

How are we changing clinical trials?

How are we changing clinical trials?

Publications

Generating Digital Control Subjects using Machine Learning for Alzheimer's Disease Clinical Trials (CTAD 2019)

The ability to reduce the burden on control subjects with subjects in clinical trials for complex diseases like Alzheimer’s Disease would drastically improve the search for beneficial therapies.
Publications

Digital Control Subjects for Alzheimer's Disease Clinical Trials (AMIA 2019)

Blog

Reflections on AAIC 2019: Community, Cause, and Challenges

Blog

Learning from Data Across the Alzheimer's Disease Spectrum

At AAIC, I watched the talks with this question in mind: how would we build a model of disease progression in the early stages of AD?
While treating the patient is the utmost priority, we need to understand that Alzheimer’s impacts every part of a person’s life and to address all of those parts, both effectively and compassionately.
The ability to simulate dozens of clinical characteristics simultaneously is a powerful tool to model disease progression. Such models have useful applications for clinical trials, from analyzing cont

Machine learning for comprehensive forecasting of Alzheimer's Disease progression

Generating Digital Twins with Multiple Sclerosis Using Probabilistic Neural Networks

Multiple Sclerosis (MS) is a neurodegenerative disorder characterized by a complex set of clinical assessments. We use an unsupervised machine learning model called...
No items found.
No items found.
No items found.
No items found.
No items found.

Contact us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.